Asthma Clinical Trials

Find Asthma Clinical Trials Near You

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma

Status: Recruiting
Location: See all (93) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY

The objective of this study is to assess the potential for GB-0895 treatment to improve the health of adolescents and adults with severe asthma that is uncontrolled by inhaled corticosteroids (ICS) and conventional asthma controllers. The study details include: Study treatment: randomized to receive either GB-0895 or placebo administered every 6 months over 52 weeks. Visit frequency: every 1-2 months after the first month.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 12
Maximum Age: 80
Healthy Volunteers: f
View:

• Adults and adolescents ≥ 12 and ≤ 80 years of age.

• Documented physician diagnosis of asthma for ≥ 2 years.

• Subjects must be on medium to high dose ICS for ≥ 12 months before Screening Visit 1 plus at least 1 additional asthma controller (e.g., LABA, LAMA) ≥ 3 months before Screening Visit 1 with no change in ICS or controller(s) for at least three months.

• Subjects must have a well-documented history of at least two asthma exacerbations requiring systemic corticosteroid treatment despite the use of medium-to-high dose ICS in the past 12 months before Screening Visit 1.

• Adults ≥ 18 years of age at Screening Visit 1, a pre-BD FEV1 \<80% predicted at Screening Visit 1.

• Adolescents 12 to \< 18 years of age at Screening Visit 1: A pre-BD FEV1 \< 90% predicted OR, FEV1:Forced Vital Capacity (FVC) ratio \< 0.80.

• Positive BD responsiveness test: Increase of at least 12% and 200 mL in FEV1 between 15 and 60 minutes after the administration of a short-acting β2-agonist (SABA) at least once during the screening period.

• ACQ-6 score ≥ 1.5 at the Screening Visit.

• Weight ≥40 kg at the Screening Visit 1

Locations
United States
California
Research Site 23
RECRUITING
Northridge
Research Site 26
RECRUITING
Pasadena
Research Site 29
RECRUITING
Rancho Cucamonga
Research Site 34
RECRUITING
Valencia
Research Site 13
RECRUITING
West Hills
Colorado
Research Site 15
RECRUITING
Colorado Springs
Florida
Research Site 32
RECRUITING
Brooksville
Research Site 12
RECRUITING
Doral
Research Site 14
RECRUITING
Gainesville
Research Site 03
RECRUITING
Hialeah
Research Site 25
RECRUITING
Kendall
Research Site 04
RECRUITING
Miami
Research Site 01
RECRUITING
Miami Lakes
Research Site 08
RECRUITING
North Miami
Research Site 10
RECRUITING
Palm Springs
Research Site 02
RECRUITING
Tampa
Georgia
Research Site 18
RECRUITING
Rincon
Illinois
Research Site 31
RECRUITING
Glenview
Maryland
Research Site 16
RECRUITING
Baltimore
Research Site 28
RECRUITING
Columbia
Research Site 20
RECRUITING
Towson
Michigan
Research Site 06
RECRUITING
Flint
Mississippi
Research Site 30
RECRUITING
Olive Branch
North Carolina
Research Site 27
RECRUITING
Gastonia
Research Site 83
RECRUITING
Winston-salem
New York
Research Site 37
RECRUITING
The Bronx
Texas
Research Site 24
RECRUITING
Amarillo
Research Site 19
RECRUITING
Baytown
Research Site 07
RECRUITING
Dallas
Research Site 17
RECRUITING
Dallas
Research Site 09
RECRUITING
Houston
Research Site 11
RECRUITING
Houston
Research Site 22
RECRUITING
Kerrville
Research Site 05
RECRUITING
Lewisville
Research Site 33
RECRUITING
Mckinney
Utah
Research Site 21
RECRUITING
Riverton
Other Locations
Bulgaria
Research Site 56
RECRUITING
Haskovo
Research Site 38
RECRUITING
Kozloduy
Research Site 54
RECRUITING
Pleven
Research Site 55
RECRUITING
Plovdiv
Research Site 73
RECRUITING
Rousse
Research Site 88
RECRUITING
Rousse
Research Site 63
RECRUITING
Sofia
Research Site 65
RECRUITING
Sofia
Research Site 69
RECRUITING
Sofia
Research Site 75
RECRUITING
Sofia
Research Site 81
RECRUITING
Sofia
Research Site 91
RECRUITING
Sofia
Research Site 95
RECRUITING
Sofia
Research Site 39
RECRUITING
Vidin
Germany
Research Site 40
RECRUITING
Berlin
Research Site 40
RECRUITING
Berlin
Research Site 44
RECRUITING
Berlin
Research Site 49
RECRUITING
Berlin
Research Site 42
RECRUITING
Deggingen
Research Site 36
RECRUITING
Frankfurt Am Main
Research Site 67
RECRUITING
Frankfurt Am Main
Research site 79
RECRUITING
Leipzig
Research Site 92
RECRUITING
Leipzig
Research Site 43
RECRUITING
Lübeck
Research Site 43
RECRUITING
Lübeck
Research Site 80
RECRUITING
München
Research Site 76
RECRUITING
Witten
Greece
Research Site 90
RECRUITING
Athens
Research Site 82
RECRUITING
Thessaloniki
Hungary
Research Site 45
RECRUITING
Budapest
Research Site 47
RECRUITING
Mosonmagyaróvár
Research Site 53
RECRUITING
Szigetvár
Research Site 46
RECRUITING
Szombathely
Research Site 78
RECRUITING
Szombathely
Latvia
Research Site 52
RECRUITING
Riga
Research Site 70
RECRUITING
Riga
Research Site 71
RECRUITING
Riga
Netherlands
Research Site 77
RECRUITING
Enschede
Research Site 62
RECRUITING
Heerlen
Portugal
Research Site 48
RECRUITING
Figueira Da Foz Municipality
Research Site 74
RECRUITING
Porto
Romania
Research Site 50
RECRUITING
Brasov
Research Site 35
RECRUITING
Bucharest
Research Site 84
RECRUITING
Bucharest
Research Site 64
RECRUITING
Cluj-napoca
Research Site 66
RECRUITING
Cluj-napoca
Research Site 87
RECRUITING
Cluj-napoca
Research Site 51
RECRUITING
Craiova
Research Site 41
RECRUITING
Oradea
Research Site 72
RECRUITING
Timișoara
South Africa
Research Site 68
RECRUITING
Cape Town
Research Site 58
RECRUITING
Durban
Research Site 59
RECRUITING
Johannesburg
Research Site 89
RECRUITING
Johannesburg
Research Site 60
RECRUITING
Kwadukuza
Research Site 57
RECRUITING
Sydenham
Research Site 61
RECRUITING
Welkom
Contact Information
Primary
Generate Recruitment
solairiastudy@generatebiomedicines.com
888-469-0033
Time Frame
Start Date: 2025-12-03
Estimated Completion Date: 2028-12
Participants
Target number of participants: 786
Treatments
Experimental: GB-0895
GB-0895 Subcutaneous (SC) injection
Placebo_comparator: Placebo
Placebo Subcutaneous (SC) injection
Related Therapeutic Areas
Sponsors
Leads: Generate Biomedicines

This content was sourced from clinicaltrials.gov